Treatment-resistant Depression Market Size & Growth Analysis to 2030

The global treatment-resistant depression market size is projected to grow at a significant CAGR of around 4% during the forecast period from 2024 to 2030. The market is predominantly propelled by the surge in depression cases, heightened awareness regarding depression, and the introduction of innovative pharmaceuticals. According to the World Health Organization (WHO) data updated in June 2021, over 700,000 people succumb to suicide annually, making it the fourth leading cause of death among 15-19-year-olds. The market’s expansion is further catalyzed by manufacturers’ keen interest in developing new medications, with approvals from the United States Food and Drug Administration (USFDA) playing a pivotal role. For instance, in July 2022, Abbott obtained USFDA approval for the utilization of its deep brain stimulators (DBS) device in treating treatment-resistant depression (TRD). Additionally, in March 2019, the FDA sanctioned Spravato, a non-competitive N-methyl D-aspartate (NMDA) receptor antagonist, in conjunction with an oral antidepressant, for treating TRD in adults. This marked the first-ever approval of an NMDA therapy for TRD.

Furthermore, the escalating prevalence of TRD, characterized by depression resistant to conventional therapies, propels the demand for innovative treatments. Ongoing research and development efforts in psychiatry and neuroscience contribute to the discovery of novel therapeutic targets and advanced interventions. Increasing awareness among healthcare professionals and the public, coupled with a growing emphasis on mental health, leads to earlier diagnosis and intervention. Collaborations between pharmaceutical entities, research institutions, and healthcare organizations accelerate the development of new TRD therapies. Government initiatives, technological advancements, patient advocacy, and the market entry of novel treatments further bolster the TRD market, creating a dynamic landscape that evolves with scientific progress and changing healthcare priorities.

Market Snapshot:

To know more about the research study, request sample papers

Market Drivers:

• Increasing Prevalence of Treatment-Resistant Depression: The rising incidence and prevalence of treatment-resistant depression contribute to the expansion of the market. As more individuals experience depression that does not respond to traditional treatments, the demand for alternative and advanced therapies increases.
• Advancements in Research and Development: Ongoing research and development activities in the field of psychiatry and neuroscience contribute to the identification of new therapeutic targets and innovative treatment approaches for TRD. Breakthroughs in understanding the neurobiology of depression can lead to the development of more effective interventions.
• Growing Awareness and Diagnosis: Increased awareness about treatment-resistant depression among healthcare professionals and the general public leads to earlier diagnosis and intervention. This awareness contributes to the overall growth of the TRD market as more individuals seek specialized treatments.
• Rising Healthcare Expenditure: The overall increase in healthcare expenditure, both by individuals and governments, allows for greater investment in mental health research and the development of new treatment options for TRD.
• Collaborations and Partnerships: Collaborations between pharmaceutical companies, research institutions, and healthcare organizations foster the exchange of knowledge and resources. These partnerships can accelerate the development and commercialization of new therapies for TRD.
• Government Initiatives and Support: Government initiatives aimed at improving mental health and well-being, along with supportive policies, can drive investment in research and development for TRD treatments. Funding and grants for innovative projects in this area contribute to market growth.
• Technological Advancements: Advances in technology, such as the use of neuroimaging, pharmacogenomics, and personalized medicine, enable more precise diagnosis and targeted treatment strategies for TRD. Technological innovations can attract investments and drive market expansion.
• Patient Advocacy and Support Groups: Patient advocacy groups and support organizations play a crucial role in raising awareness, reducing stigma, and advocating for better treatment options for individuals with TRD. Their efforts contribute to a more supportive environment for research and development in this field.

Market Insights:

The global treatment-resistant depression market is bifurcated into drug class, route of administration, distribution channel, and geography. On the basis of drug class, the market is further segmented into selective serotonin reuptake inhibitors (SSRIS), monoamine oxidase inhibitors, tricyclic antidepressant, and others. The selective serotonin reuptake inhibitors (SSRIs) segment is accounted to hold the largest revenue share of the global market in the benchmark year. SSRIs continue to thrive in the pharmaceutical market for treating depression due to their proven efficacy, favorable side effect profile, and broad acceptance as first-line treatments. Their mechanism of increasing serotonin levels in the brain, coupled with a generally well-tolerated nature, enhances patient adherence. SSRIs are widely prescribed across various medical specialties, contributing to their broad market reach. The safety and tolerability of SSRIs, especially when compared to older antidepressant classes, make them a preferred choice for healthcare professionals. The availability of generic versions further increases accessibility. Ongoing research and development efforts, exploring new SSRIs and related compounds, contribute to the sustained growth of this class.

• Selective Serotonin Reuptake Inhibitors (SSRIs): SSRIs are among the most commonly prescribed antidepressants and work by increasing the levels of serotonin in the brain. While effective for many individuals with depression, some patients may not respond adequately to SSRIs, leading to the classification of their depression as treatment-resistant.
• Monoamine Oxidase Inhibitors (MAOIs): MAOIs are another class of antidepressants that work by inhibiting the activity of monoamine oxidase, an enzyme that breaks down neurotransmitters such as serotonin, dopamine, and norepinephrine. They are used less frequently than SSRIs due to their potential side effects and interactions with certain foods and medications.
• Tricyclic Antidepressants (TCAs): TCAs are an older class of antidepressants that are sometimes used when other medications have failed. They work by increasing the levels of serotonin and norepinephrine in the brain. Like MAOIs, TCAs are associated with a range of side effects and are less commonly prescribed compared to SSRIs.
• Others: This category may include various other classes of antidepressants such as serotonin-norepinephrine reuptake inhibitors (SNRIs), atypical antidepressants, and novel therapies that target different neurotransmitter systems or mechanisms of action. Additionally, it may encompass adjunctive therapies like antipsychotics, mood stabilizers, or ketamine infusion therapy, which are sometimes used in combination with antidepressants for TRD treatment.

The treatment-resistant depression market research report presents the analysis of each segment from 2021 to 2030 considering 2023 as the base year for the research. The compounded annual growth rate (CAGR) for each respective segment is calculated for the forecast period from 2024 to 2030.

Historical & Forecast Period

• 2020-22 – Historical Year
• 2023 – Base Year
• 2024-2030 – Forecast Period

Market Segmentation:

By Drug Class:

• Selective Serotonin Reuptake Inhibitors (SSRIS)
• Monoamine Oxidase Inhibitors
• Tricyclic Antidepressant
• Others

By Route of Administration:

• Oral
• Parenteral
• Others

By Distribution Channel:

• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy

By Region:

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Regional Analysis:

Geographically, North America dominated the global treatment-resistant depression market in the benchmark year 2023 and expected to grow at the same trend over the forecast period. The region boasts a well-established healthcare infrastructure, particularly in the United States and Canada, facilitating efficient diagnosis and treatment of mental health conditions, including TRD. Additionally, North America serves as a major hub for pharmaceutical research and development, fostering continuous innovation in mental health therapeutics.

Furthermore, the high prevalence of mental health disorders, coupled with robust insurance coverage and reimbursement policies, further contributes to the widespread adoption of TRD treatments in the region. The regulatory environment, led by the United States Food and Drug Administration (USFDA), plays a crucial role in timely drug approvals, allowing for the introduction of new and advanced therapies to address treatment-resistant depression. Furthermore, efforts to increase mental health awareness and reduce stigma have led to a higher rate of individuals seeking effective treatments for TRD in North America.

Competitive Assessment:

Some of the prominent market players operating in the global Treatment-Resistant Depression market are Pfizer Inc. Mylan N.V., Novartis AG, Hikma Pharmaceuticals plc, and Aurobindo Pharma. Companies are exploring markets by expansion, new investment, the introduction of new services, and collaboration as their preferred strategies. Players are exploring new geography through expansion and acquisition to gain a competitive advantage through joint synergy.

Recent Developments:

• In August 2022, Merck Sharp & Dohme LLC commenced a Phase II A Clinical Trial to assess the safety and effectiveness of MK-1942 in individuals with treatment-resistant depression. The initiative aims to advance the understanding of MK-1942’s potential as a therapeutic option for this patient population.
• Similarly, in July 2022, Novartis Pharmaceuticals announced plans to launch a Phase 2 clinical trial for MIJ821 (ketamine) in September 2022, focusing on its efficacy in treating treatment-resistant depressive disorders. This undertaking reflects Novartis’ commitment to exploring innovative solutions for individuals facing challenges with conventional depression treatments.
• In May 2022, COMPASS Pathways unveiled positive data from the Phase IIb study of COMP360 psilocybin therapy for treatment-resistant depression at the American Psychiatric Association annual meeting in New Orleans, highlighting promising results in the ongoing pursuit of alternative treatment modalities.
• Furthermore, in February 2022, Denova Biopharma received approval from the USA FDA to initiate a Phase 2b clinical trial, examining the efficacy and safety of DB104 (liafensine) in patients with a treatment-resistant mood disorder, signaling advancements in research and development efforts for novel therapeutic options.

Key Companies:

• Pfizer Inc (U.S.)
• Mylan N.V. (U.S.)
• Novartis AG (Switzerland)
• Hikma Pharmaceuticals plc (U.K.)
• Aurobindo Pharma (India)
• AbbVie Inc. (U.S.)
• Melinta Therapeutics, Inc (U.S.)
• Bristol-Myers Squibb Company (U.S.)
• GSK plc. (U.K.)
• Bayer AG (Germany)
• Lupin (India)

Key Questions Answered by Treatment-Resistant Depression Market Report

• Global treatment-resistant depression market forecasts from 2024-2030
• Regional market forecasts from 2024-2030 covering Asia-Pacific, North America, Europe, Middle East & Africa, and Latin America
• Country-level forecasts from 2024-2030 covering 15 major countries from the regions as mentioned above
• Treatment-resistant depression submarket forecasts from 2024-2030 covering the market by drug class, route of administration, distribution channel, and geography
• Various industry models such as SWOT analysis, Value Chain Analysis about the market
• Analysis of the key factors driving and restraining the growth of the global, regional, and country-level treatment-resistant depression markets from 2024-2030
• Competitive Landscape and market positioning of top 10 players operating in the market